Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Amicoat AS currently manages 2 pending office actions within the Biotechnology & Pharmaceuticals technology area. This count of 2 pending office actions represents the active workload for the company as it seeks to protect its biological innovations. In the Biotechnology & Pharmaceuticals sector, these filings often require detailed experimental data to overcome stringent enablement and specificity requirements during examination.
The prosecution is distributed across 2 distinct examiners and 2 distinct art units. Having 2 distinct examiners ensures that the portfolio is not subject to the singular perspective of one individual, providing a broader range of feedback from the patent office. The presence of 2 distinct art units indicates that the underlying technology spans multiple specialized technical classifications within the USPTO.
ALAM, AYAAN A is the busiest examiner for this portfolio, currently handling 1 pending office action. Because 1 pending office action is assigned to this specific examiner, their individual review style and historical allowance rates will directly influence the immediate outcome of the application. Practitioners should analyze the past behavior of ALAM, AYAAN A to navigate the 1 pending office action effectively.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| ALAM, AYAAN A | 1 | 38.8% | +36.4% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18001382 | ANTIMICROBIAL FORMULATIONS COMPRISING SILICONE | ALAM, AYAAN A | — |
| Art Unit | Apps |
|---|---|
| 1611 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18001382 | ANTIMICROBIAL FORMULATIONS COMPRISING SILICONE | ALAM, AYAAN A | 1611 | §103 | Non-Final OA | — | Pending | Dec 09, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialAmicoat AS has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Ayaan A Alam has the most, with 1 of Amicoat AS's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
